The Risk of Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Receiving Tocilizumab: A Systematic Review and Meta-Analysis.
Ping-Hung KoMeng Hsuan KuoI-Ting KaoChen-Yi WuChih-Wei TsengShih-Chieh ShaoPublished in: Viruses (2024)
cannot be ignored but may be avoided. Clinicians should consider implementing appropriate antiviral prophylaxis and monitoring policies for RA patients to avoid unnecessary hepatic side effects from tocilizumab treatment.
Keyphrases
- rheumatoid arthritis
- hepatitis b virus
- disease activity
- end stage renal disease
- ejection fraction
- newly diagnosed
- ankylosing spondylitis
- public health
- rheumatoid arthritis patients
- prognostic factors
- interstitial lung disease
- juvenile idiopathic arthritis
- peritoneal dialysis
- liver failure
- systemic lupus erythematosus
- patient reported outcomes
- replacement therapy